TScan Therapeutics Reports Third Quarter 2026 Financial Results and Strategic Reorganization
TScan Therapeutics announced a strategic reorganization to prioritize its in vivo-engineered TCR-T cell therapy program for solid tumors while pausing enrollment in its Phase 3 ALLOHA-2 study.